Krabeva 100 mg Injection
  1. Home
  2. Pharma Products
  3. Biocon
  4. Krabeva 100 mg Injection

Krabeva 100 mg Injection

Krabeva 100 mg Injection contains bevacizumab, a targeted monoclonal antibody used to treat several types of cancer. It is supplied as a 100 mg/4 mL solution for intravenous infusion. Bevacizumab works by blocking VEGF and reducing the blood-vessel formation that tumors need for growth.

BUY NOW

Category

Krabeva 100 mg Injection is used with appropriate anticancer treatments for conditions including colorectal cancer, non-small cell lung cancer, kidney cancer, ovarian cancer, and cervical cancer. Bevacizumab binds to vascular endothelial growth factor and inhibits the formation of new blood vessels that support tumor growth. It is administered by intravenous infusion under the supervision of a qualified healthcare professional. Patients require monitoring for blood pressure changes, bleeding, infusion reactions, and other treatment-related effects.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 100 mg
Concentration 25 mg/mL
Dosage Form Concentrate for Solution for Infusion
Route of Administration Intravenous Infusion
Pack Size 1 Vial, 4 mL

Product Also Known As

Krabeva 100 mg Injection, Bevacizumab 100 mg Injection, Krabeva Bevacizumab Injection, Bevacizumab Cancer Injection, Anti-VEGF Injection, Targeted Cancer Therapy Injection